Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 2 4Phase 1 4

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Breast 1

Conditions

Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Kidney Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Interventional × CB-839 × Clear all
NCT03428217 2023-03-20

CANTATA

Calithera Biosciences, Inc

Phase 2 Completed
444 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03057600 2022-09-28

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Calithera Biosciences, Inc

Phase 2 Completed
52 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

NCT04265534 2022-09-21

KEAPSAKE

Calithera Biosciences, Inc

Phase 2 Terminated
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03163667 2022-09-15

ENTRATA

Calithera Biosciences, Inc

Phase 2 Completed
69 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡